Stemline Therapeutics, Inc.
STML
STML was delisted on the 9th of June, 2020.
79 hedge funds and large institutions have $143M invested in Stemline Therapeutics, Inc. in 2017 Q3 according to their latest regulatory filings, with 13 funds opening new positions, 20 increasing their positions, 23 reducing their positions, and 4 closing their positions.
225% more first-time investments, than exits
New positions opened: 13 | Existing positions closed: 4
23% more capital invested
Capital invested by funds: $116M → $143M (+$27M)
13% more funds holding
Funds holding: 70 → 79 (+9)
13% less repeat investments, than reductions
Existing positions increased: 20 | Existing positions reduced: 23
28% less call options, than puts
Call options by funds: $1.22M | Put options by funds: $1.7M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Adage Capital Partners
Boston,
Massachusetts
|
+$6.18M |
| 2 |
LSC
Lyon Street Capital
Sausalito,
California
|
+$3.91M |
| 3 |
CWG
C WorldWide Group
Copenhagen,
Denmark
|
+$1.5M |
| 4 |
CCM
Consonance Capital Management
New York
|
+$954K |
| 5 |
Dimensional Fund Advisors
Austin,
Texas
|
+$929K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
-$5.05M |
| 2 |
Millennium Management
New York
|
-$2.91M |
| 3 |
IBT
International Biotechnology Trust
London,
United Kingdom
|
-$2.54M |
| 4 |
SM
Sabby Management
Miami Beach,
Florida
|
-$1.35M |
| 5 |
CCI
Columbus Circle Investors
|
-$523K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
EWM
76
Edge Wealth Management
New York
| $6K | – | – | – |
|
|
KF
77
Krilogy Financial
St. Louis,
Missouri
| $3K | – | – | – |
|
78
SEI Investments
Oaks,
Pennsylvania
| $1K | -$8.18K | -870 | -87% |
|
79
Citigroup
New York
| $1K | -$1.62K | -172 | -71% |
|
|
TI
80
Trexquant Investment
Stamford,
Connecticut
| – | -$304K | -33,017 | Closed |
|
|
EMG
81
Ellington Management Group
Old Greenwich,
Connecticut
| – | -$160K | -17,400 | Closed |
|
|
PAM
82
Paradigm Asset Management
New York
| – | -$72.7K | -7,900 | Closed |
|
|
MAM
83
Meeder Asset Management
Dublin,
Ohio
| – | -$2K | -237 | Closed |
|
STML Hedge Fund Activity: Q3 2017 in Review
79 of the 4,011 institutional investors tracked by Wall St. Rank reported a position in Stemline Therapeutics, Inc. (STML) for Q3 2017, worth a combined $143M — up 23% from $116M a quarter earlier.
Buyers outnumbered sellers: 13 funds opened new STML positions and 4 closed out — a net gain of 9 holders — while 20 added to existing stakes and 23 trimmed.
The largest buyer was Adage Capital Partners, opening a new position worth an estimated $6.18M. The largest seller was Fidelity Investments, cutting an estimated $5.05M.
- 79 institutional investors held Stemline Therapeutics, Inc. (STML) as of Q3 2017, up from 70 in Q2 2017.
- Funds reported $143M of Stemline Therapeutics, Inc. stock for Q3 2017, up 23% quarter-over-quarter.
- 13 funds opened new Stemline Therapeutics, Inc. positions in Q3 2017 and 4 closed out, a net change of +9 holders.
- The largest Stemline Therapeutics, Inc. buyer in Q3 2017 was Adage Capital Partners, an estimated $6.18M added.
- The largest Stemline Therapeutics, Inc. seller in Q3 2017 was Fidelity Investments, an estimated $5.05M sold.
Based on aggregated 13F filings for Q3 2017.